The aim of the current trial is to evaluate the efficacy and safety of flat-dose nivolumab (40 mg) in combination with AVD in the management of patients with newly diagnosed advanced classic Hodgkin Lymphoma
Phase:
PHASE2
Details
Lead Sponsor:
National Medical Research Radiological Centre of the Ministry of Health of Russia